or Try an Advanced Search...

    ETF Components for CNBS - Amplify Seymour Cannabis ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    IIPR F 1.79 7.93
    TLRY F 4.26 7.08
    MAPS B -3.39 5.80
    GRWG F 7.30 4.02
    SNDL F 4.08 2.66
    REFI A 0.50 2.18
    OGI F 3.38 1.15
    HYFM D 2.62 0.41
    JAZZ B 2.73 0.30
    CARA D 3.28 0.09

    Represented by ETF Holdings

    Keywords: Cannabis Entheogens Euphoriants Medicinal Plants Medicine Aeroponics Biopharmaceutical Cannabis Products Cannabis Smoking Chronic Pain Drugs Health Sciences Herbalism Hydroculture Hydroponics Medical Cannabis Pain Plants Psychoactive Drugs Real Estate Investment Trust
    Industries: Drug Manufacturers - Specialty & Generic Biotechnology Conglomerates Farm & Heavy Construction Machinery Home Improvement Retail REIT - Industrial REIT - Mortgage

    Recent News for Amplify Seymour Cannabis ETF & its Holdings

    Date Stock Title
    Nov 21 TLRY Redhook Brewery and Montlake Futures Team Up to Launch Montlake Gameday Gold Lager, a New Craft Beer in Support of University of Washington Athletes
    Nov 21 TLRY Tilray Brands Unveils 2024 Holiday Cannabis Gift Guide
    Nov 21 JAZZ Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer
    Nov 21 TLRY Tilray Brands Gets Festive with its 2024 Holiday Beverage Gift Guide
    Nov 21 JAZZ Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
    Nov 21 JAZZ Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
    Nov 20 TLRY Tilray Brands, Inc. (TLRY) Stock Moves -1.53%: What You Should Know
    Nov 20 TLRY Prediction: Tilray Brands Won't Be a Cannabis Company in 5 Years
    Nov 20 IIPR 3 Dividend Stocks On US Exchanges Offering Up To 7.3% Yield
    Nov 20 TLRY Exploring ACNB And 2 More Undervalued Small Caps With Insider Buying In US
    Nov 20 TLRY Beverages, Alcohol and Tobacco Stocks Q3 Recap: Benchmarking Tilray Brands (NASDAQ:TLRY)
    Nov 19 JAZZ Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
    Nov 19 JAZZ Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
    Nov 19 JAZZ Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment
    Nov 19 TLRY Tilray Stock Hits 52-Week Low: A Buying Opportunity or a Warning Sign?
    Nov 19 GRWG GrowGeneration Unveils New Product Lines Across Its Proprietary Brands Portfolio
    Nov 19 TLRY Q3 Earnings Outperformers: Celsius (NASDAQ:CELH) And The Rest Of The Beverages, Alcohol and Tobacco Stocks
    Nov 18 JAZZ Jazz Pharmaceuticals: High Uncertainty, Low Risk
    Nov 18 JAZZ Is Jazz Pharmaceuticals plc (JAZZ) the Best Immunotherapy Stock to Buy Now?
    Nov 18 TLRY Weekly Roundup on the Cannabis Sector & Psychedelic Sector
    The investment seeks to provide investors capital appreciation. The fund will invest at least 80% of its net assets (including investment borrowings) in the securities of companies that derive 50% or more of their revenue from the cannabis and hemp ecosystem. It is an actively managed ETF that seeks to provide investment exposure to global companies principally engaged in the emerging cannabis and hemp ecosystem across one of three classifications. The fund is non-diversified.
    Exchange Traded Funds Cannabis Hemp
    Back to the Main CNBS Page...